NCT06385483 2026-03-19
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT04497584 2025-10-01
Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT05215548 2025-02-19
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
National Taiwan University Hospital
Phase 2 Active not recruiting
NCT01553942 2024-11-20
Afatinib With CT and RT for EGFR-Mutant NSCLC
Massachusetts General Hospital
Phase 2 Active not recruiting